Belantamab Mafodotin Offers New Options for Patients with Multiple Myeloma

Video

The drug is approved for patients after 4 or more failed lines of therapy, although many patients in clinical trials had received 7 or more prior lines of therapy.

In a recent interview with Pharmacy Times, Robert Mancini, PharmD, BCOP, FHOPA, said the recent FDA approval of belantamab mafodotin has provided a much-needed new option for patients with multiple myeloma.

Mancini said the drug is approved for patients after 4 or more failed lines of therapy, although many patients in clinical trials had received 7 or more prior lines of therapy. Although he said this approval does not entirely shift the treatment landscape for multiple myeloma, Mancini said this approval can offer extended survival for patients with the incurable disease.

Related Videos
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 11 - "Complying with REMS Training and Documentation Requirements"
© 2024 MJH Life Sciences

All rights reserved.